ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	NT$13.75	-5.82%	128,463
05/11/26	NT$14.60	-1.02%	32,852
04/11/26	NT$14.75	-1.34%	54,018
03/11/26	NT$14.95	-1.97%	80,563
02/11/26	NT$15.25	+2.35%	15,951

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 06/11/2026			5-day change	1st Jan Change
13.75 ^TWD	-5.82%		-7.72%	-33.25%

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	992M 30.25M 27.13M 24.8M 22.64M 42.65M 2.84B 43.99M 299M 119M 1.52B 114M 111M 4.79B	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	937M 28.59M 25.64M 23.43M 21.39M 40.3M 2.69B 41.57M 282M 113M 1.43B 107M 105M 4.53B	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

10-15	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
08-12	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-08	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/08/25	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/04/25	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
13/03/24	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/04/23	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
26/04/22	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
14/08/21	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
22/04/21	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 day	-5.82%
1 week	-7.72%
Current month	-7.72%
1 month	-16.41%
3 months	-18.15%
6 months	-27.44%
Current year	-33.25%

Enimmune corporation Stock

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	13.55	15.25
1 month	13.55	16.95
Current year	13.55	22.15
1 year	13.55	22.55
3 years	13.55	49.3
5 years	13.55	75.3
10 years	13.55	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	07/01/2019
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	21/07/2014
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Cheng Liu CHM	Chairman	-	07/01/2019
Fei Pan BRD	Director/Board Member	-	02/01/2014
Chin Yi Chiu BRD	Director/Board Member	-	19/05/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	-5.82%	-7.72%	-33.25%	-62.38%	30.25M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+62.02%	66.7B
ARGENX SE	+4.36%	+8.83%	+14.49%	+85.28%	56.88B
LONZA GROUP AG	+0.84%	+3.30%	+25.39%	+97.41%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+103.27%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+36.08%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+807.84%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+53.61%	35.35B
GENMAB A/S	+3.46%	-0.89%	+95.41%	+66.97%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+381.71%	25.1B
Average	+1.76%	+1.40%	+41.70%	+163.18%	40.67B
Weighted average by Cap.	+2.13%	+3.07%	+50.70%	+167.69%

	2024	2025
Net sales	39.92M 1.22M 1.09M 998K 911K 1.72M 114M 1.77M 12.03M 4.8M 61.06M 4.57M 4.47M 193M	48.19M 1.47M 1.32M 1.2M 1.1M 2.07M 138M 2.14M 14.52M 5.79M 73.73M 5.52M 5.4M 233M
Net income	-158M -4.81M -4.31M -3.94M -3.6M -6.77M -452M -6.99M -47.48M -18.93M -241M -18.04M -17.65M -761M	-164M -5.01M -4.5M -4.11M -3.75M -7.07M -471M -7.29M -49.53M -19.75M -251M -18.82M -18.41M -794M
Net Debt	-382M -11.65M -10.45M -9.55M -8.72M -16.43M -1.1B -16.94M -115M -45.9M -584M -43.73M -42.8M -1.84B	-54.59M -1.67M -1.49M -1.36M -1.25M -2.35M -157M -2.42M -16.45M -6.56M -83.52M -6.25M -6.12M -264M